AB

Akshat Bhanukumar Patel

Active Director Whole-Time Director DIN 00151091
DIN 00151091 First appointment Dec 2004 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 3 historical roles
Total affiliations 6 Since Dec 2004
Shareholding value •••• Premium profile

About Akshat Bhanukumar Patel

Data last updated:

Akshat Bhanukumar Patel is a Whole-Time Director at Alferez Private Limited (since 2011), Director at Naira Properties Private Limited (since 2022) and Director at Alferez Healthcare Private Limited (since 2024). The companies operate in Pharma, Real Estate and Information Technology. The 2 current companies with reported revenue have a combined latest revenue of ₹5.75 Cr; the largest is Alferez Private Limited at ₹5.74 Cr (FY 2025). Earlier, Akshat Bhanukumar Patel was a Nominee Director at Osaka Pharmaceuticals Private Limited (2004–2014) and Designated Partner at Pius Solutions Llp (2010–2011) and 1 more.

DIN 00151091
Primary Designation Whole-Time Director
Industry Pharma
First Appointment 10 Dec 2004
Oldest Company Age 31 yrs
Largest company Alferez Private Limited · ₹5.74 Cr (FY 2025)
Combined revenue ₹5.75 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Alferez Private Limited U45202GJ1995PTC027014
Whole-Time Director26 Feb 20111995₹5.74 Cr (FY 2025)Active
Naira Properties Private Limited U70109GJ2022PTC131680
Director05 May 20222022₹1 Lakh (FY 2024)Active
Alferez Healthcare Private Limited U46497GJ2024PTC152028
Director31 May 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Nominee Director10 Dec 20042004₹24.38 Cr (FY 2025)Active
Designated Partner09 Jun 20102010Strike Off
Designated Partner09 Jun 20102010Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Akshat Bhanukumar Patel

NameDINCompanyDesignation
Kamleshkumar Patel08084935Alferez Private Limited , Naira Properties Private Limited and 1 moreDirector

Directorship timeline

Open interactive timeline →
Alferez Private Limited
Naira Properties Private Limited
Alferez Healthcare Private Limited
Osaka Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Akshat Bhanukumar Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Akshat Bhanukumar Patel

Akshat Bhanukumar Patel currently holds 3 directorships: Alferez Private Limited (Whole-Time Director, since 26 Feb 2011, revenue ₹5.74 Cr (FY 2025)); Naira Properties Private Limited (Director, since 05 May 2022, revenue ₹1 Lakh (FY 2024)); Alferez Healthcare Private Limited (Director, since 31 May 2024).

Akshat Bhanukumar Patel was first appointed on 10 Dec 2004 as Nominee Director at Osaka Pharmaceuticals Private Limited. The most recent appointment on record is 31 May 2024 at Alferez Healthcare Private Limited.

The 2 current companies of Akshat Bhanukumar Patel that report revenue have a combined latest revenue of ₹5.75 Cr: Alferez Private Limited ₹5.74 Cr (FY 2025); Naira Properties Private Limited ₹1 Lakh (FY 2024).

Akshat Bhanukumar Patel held 3 earlier board appointments: Osaka Pharmaceuticals Private Limited (Nominee Director, 10 Dec 2004 to 15 Apr 2014); Pius Solutions Llp (Designated Partner, 09 Jun 2010 to 14 Feb 2011); Colorama Pharmex Llp (Designated Partner, 09 Jun 2010 to 14 Feb 2011).

The current boards of Akshat Bhanukumar Patel's companies include Kamleshkumar Patel (Alferez Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available